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Abstract
The success of anticancer therapy is usually limited by the development of drug resistance. Such 
acquired resistance is driven, in part, by intratumoural heterogeneity — that is, the phenotypic 
diversity of cancer cells co-inhabiting a single tumour mass. The introduction of the cancer stem 
cell (CSC) concept, which posits the presence of minor subpopulations of CSCs that are uniquely 
capable of seeding new tumours, has provided a framework for understanding one dimension of 
intratumoural heterogeneity. This concept, taken together with the identification of the epithelial-
to-mesenchymal transition (EMT) programme as a critical regulator of the CSC phenotype, offers 
an opportunity to investigate the nature of intratumoural heterogeneity and a possible mechanistic 
basis for anticancer drug resistance. In fact, accumulating evidence indicates that conventional 
therapies often fail to eradicate carcinoma cells that have entered the CSC state via activation of 
the EMT programme, thereby permitting CSC-mediated clinical relapse. In this Review, we 
summarize our current understanding of the link between the EMT programme and the CSC state, 
and also discuss how this knowledge can contribute to improvements in clinical practice.
The fact that most malignant tumours are composed of multiple phenotypically distinct 
subpopulations of neoplastic cells has been established by >60 years of research1-4. 
Nowadays, the phenotypic diversity of neoplastic cells within a tumour is considered a major 
driver of the development of resistance to therapy and, for this reason, is attracting 
increasing interest5. The biological heterogeneity arising through both genetic and non-
genetic mechanisms contributes to the phenotypic differences between the distinct 
subpopulations of cancer cells residing within individual tumours6,7. Advances in genome-
sequencing technologies are enabling rapid progress in delineating the types of genetic 
changes that underlie the phenotypic alteration and diversification of cancer cells8,9. In 
parallel, the ability of cancer cells to frequently interconvert between multiple alternative 
phenotypic states, doing so without concomitant mutational changes in their genomes, is 
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increasingly recognized; however, the nature of the non-genetic — that is, epigenetic — 
regulatory mechanisms that contribute substantially to the behaviours of cancer cells and the 
tumours that they form remains largely unexplored, revealing a critical need to uncover these 
mechanisms10,11.
The introduction of cancer stem cell (CSC) concept, which postulates the presence of minor 
populations of CSCs that are uniquely capable of seeding new tumours, has provided new 
insights into how epigenetic regulatory mechanisms can contribute to the phenotypic 
diversity of distinct subpopulations of cancer cells within a tumour12,13. This concept is 
based on the notion that various phenotypically distinct cancer cells residing within the same 
tumour mass are organized in a hierarchy, resembling the stem-cell hierarchy of the 
corresponding non-neoplastic tissue. Indeed, the functional parallels between CSCs and non-
neoplastic stem cells are considered to be extensive, including the unique ability to entirely 
regenerate complex neoplastic and non-neoplastic tissues, respectively, under appropriate 
conditions14. Accordingly, in tumours, the epigenetically defined state of CSCs should, in 
principle, enable the tumour cells to self-renew in order to generate new CSCs, and to spawn 
progeny that differentiate into less-tumorigenic and non-self-renewing offspring — that is, 
the non-CSCs that are thought, in most cases, to form the bulk of the tumour. Implicit in this 
paradigm is the important hypothesis that continued tumour growth, metastasis formation, 
and recurrence after therapy can largely be attributed to the relatively rare subpopulations of 
CSCs within individual tumours15,16. Notably, discrete subpopulations of CSCs have now 
been identified in many types of human cancer, demonstrating the wide applicability of the 
CSC concept17.
The penetration of the CSC concept has caused some to argue that the often limited efficacy 
of conventional anticancer therapies is attributable to the targeting of the bulk population of 
non-CSCs within individual tumours, while not eliminating the rare subpopulation of 
CSCs18-20. Indeed, accumulating evidence has shown that CSCs are more resistant than non-
CSCs to various types of conventional therapies21-23. Moreover, given their tumour-
initiating capacity, the surviving CSCs are qualified to serve as the precursors of new tumour 
masses, ultimately leading to clinical relapse. These observations highlight the critical 
importance of understanding the epigenetic mechanisms that distinguish CSCs from the bulk 
population of non-CSCs; insights into these mechanisms hold the promise of yielding novel 
therapeutic strategies designed to eradicate CSCs, with the possible benefit of achieving 
extended, if not permanent, clinical remissions.
The epigenetic changes that account for the phenotypic differences between CSCs and non-
CSCs are only beginning to be uncovered. In the case of carcinomas, the difference between 
CSCs and non-CSCs is likely to be attributable largely to the cell-biological programme 
termed epithelial-to-mesenchymal transition (EMT)24,25. This programme imparts heritable 
phenotypic changes to carcinoma cells through epigenetic modifications without introducing 
new genetic alterations. Upon activation of the programme, carcinoma cells lose many of 
their epithelial characteristics, including the presence of epithelial cell junctions and apical–
basal polarity, and instead acquire mesenchymal attributes, such as an elongated, fibroblast-
like morphology as well as an increased capacity for migration and invasion26 (FIG. 1). In a 
number of carcinomas, only neoplastic cells within the CSC-enriched subpopulation exhibit 
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aspects of EMT-programme activation27-30. Of note, in certain experimental models of 
carcinoma, forced induction of an EMT programme in epithelial tumour cells substantially 
increases their capacity for tumour initiation27,31,32. In addition, EMT-programme activation 
confers on these tumour cells resistance to many types of therapeutic agents — another 
important attribute of CSCs33,34.
Perhaps ironically, we still possess relatively few insights into why these two clinically 
important cell-biological programmes — the CSC phenotype and EMT — are so intimately 
interconnected. Herein, we summarize our current understanding regarding the causes and 
effects of EMT-programme activation in carcinoma cells, with a particular focus on how this 
programme is linked to the CSC state. We also discuss the opportunities and challenges in 
targeting the EMT programme and, by extension, CSCs as a strategy for carcinoma 
treatment.
Principles of the EMT programme
The roles of EMT and the reverse process, mesenchymalto-epithelial transition (MET), were 
initially studied in the context of embryonic morphogenesis35,36. The findings revealed that 
during gastrulation in amniotes, the epiblast cells in a specific area of the primitive ectoderm 
— the first embryonic epithelial tissue — undergo EMT, thereby differentiating into primary 
mesenchyme cells, and ingress from the ectodermal layer, ultimately giving rise to 
mesodermal and endodermal cell layers. As a further example, neural crest cells within the 
dorsal neural tube — composed of neuroepithelial cells — also undergo EMT, migrate to 
various sites in the developing embryo, and differentiate into a variety of distinct cell types, 
including melanocytes, peripheral neurons, glial cells, and connective-tissue cells. By 
contrast, during the embryonic development of a kidney, cells in the metanephric 
mesenchyme undergo MET in order to form the renal epithelium and, ultimately, generate 
nephrons37. These examples comprise only a few of the instances in which epithelial–
mesenchymal interconversions have key roles in embryogenesis.
In addition, the EMT programme plays a central part in various pathological processes, 
including wound healing, tissue fibrosis, and carcinoma progression38,39. In all of these 
processes, activation of the EMT programme elicits changes in multiple fundamental aspects 
of cellular physiology that include: alterations in the cytoskeletal organization and associated 
changes in cell morphology from squamous, cuboidal, or columnar shapes to spindle-like, 
elongated forms (FIG. 1); dissolution of epithelial cell–cell junctions, including tight, 
adherens, and gap junctions; loss of apical–basal polarity and concomitant gain of front–rear 
polarity; acquisition of motility, as well as an ability to degrade and reorganize the 
extracellular matrix (ECM), enabling cell invasion; and reconfiguration of the expression 
patterns of at least 400 distinct genes40. Of note, both non-neoplastic and neoplastic 
epithelial cells can activate the multifaceted EMT programme to varying extents, often 
acquiring many, but not all, of the traits associated with the ‘canonical’ programme.
Various extracellular stimuli and corresponding intracellular signalling pathways have been 
implicated in the induction of EMT. The central role of TGFβ–SMAD signalling in multiple 
different models of EMT has been well established41,42. In addition, other signalling 
Shibue and Weinberg Page 3
Nat Rev Clin Oncol. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
pathways, including the canonical or noncanonical Wnt, growth factor–receptor tyrosine 
kinase, and ECM–integrin signalling pathways, acting in various combinations, also seem to 
contribute critically to the induction of EMT in a variety of tissue contexts43. Importantly, 
the EMT process operating in carcinoma cells in vivo is often, and perhaps invariably, 
triggered by specific signals released by stromal cells into the tumour microenvironment, 
some of which are also involved in choreographing various inflammatory and hypoxic 
responses44.
In both non-neoplastic and neoplastic cells, these diverse signal-transduction pathways 
converge on the activation of a relatively small group of transcription factors that proceed to 
orchestrate the gene-expression changes associated with EMT45. These transcription factors, 
often referred to collectively as ‘EMT-inducing transcription factors’ (EMT-TFs), can 
typically be classified into one of three different protein families — namely, the Snail 
(including Snail and Slug; also known as SNAI1 and SNAI2, respectively), ZEB (including 
ZEB1 and ZEB2), and basic helix–loop–helix (including TWIST1, TWIST2, and TCF3) 
families45. In certain contexts, however, other transcription factors, such as PRRX1, YAP1/
TAZ, and SOX4, also have critical roles in EMT. These master regulators of EMT 
programmes govern the transcription of EMT-associated genes via promoter activation or 
repression, often achieved through modification of chromatin structure45. The end results are 
suppression, to various extents, of genes associated with the epithelial phenotype, such as 
those encoding E-cadherin and cytokeratins, and upregulation of genes associated with the 
mesenchymal-cell phenotype, including those encoding N-cadherin, fibronectin, and 
vimentin45.
The EMT-TFs often act cooperatively to regulate the expression of common target genes 
and, in addition, frequently control the expression of one another39,45. For example, Snail is 
an upstream regulator that induces the expression of multiple other EMT-TFs, including 
SLUG, ZEB1, and TWIST1. On the other hand, TCF3 seems to function as a downstream 
effector whose expression is induced by various other EMT-TFs, such as Snail, Slug, and 
ZEB1 (REFS 40,46). Owing to these reciprocal interactions, experimental expression of one 
EMT-TF usually results in upregulation of certain other EMT-TFs, ultimately inducing, in 
many cases, the full spectrum of EMT-associated changes. Such coordinated, multifaceted 
shifts in cell phenotype can obscure the functional differences between the various 
individual EMT-TFs, which seem to be specialized for orchestrating distinct subprogrammes 
of the extensive canonical EMT programme. Moreover, the controls regulating the 
experimental expression of EMT-TFs rarely recapitulate those operating physiologically, 
resulting in phenotypic responses in cells that are not observed, for example, in 
spontaneously arising tumours. These disparities raise concerns regarding the interpretability 
of observations derived from experimental overexpression of an individual EMT-TF.
In addition to being regulated by signalling pathways, the expression and functions of EMT-
TFs are controlled by other upstream regulatory mechanisms. In particular, studies have 
highlighted the important roles of noncoding microRNAs (miRNAs), which suppress the 
expression of specific proteins through a combination of mRNA destabilization and 
translational repression47. Among the best-characterized examples of miRNAs that regulate 
the EMT programme are members of the miR-200 family, which downregulate the 
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expression of ZEB1 and ZEB2 proteins; intriguingly, the expression of miR-200 miRNAs is 
repressed, reciprocally, by ZEB1 and ZEB2, establishing a double-negative feedback 
loop48,49. Similarly, the expression of Snail is attenuated by members of the miR-34 family, 
which, in turn, is suppressed by Snail, forming another double-negative regulatory feedback 
loop between EMT-TFs and miRNAs50,51.
The expression levels of several EMT-TFs are also regulated at the level of post-translational 
protein stability: Snail is phosphorylated by GSK-3β at two consecutive serine-rich motifs, 
which targets this EMT-TF for ubiquitylation and subsequent proteasomal degradation52. By 
contrast, TWIST1 can be phosphorylated at Ser68 by ERK1/2, p38, and JNK, which protects 
this EMT-TF from ubiquitin-mediated degradation53. In addition, the Siah family of RING 
finger ubiquitin E3 ligases has a critical role in mediating the ubiquitylation and thus the 
subsequent proteasomal degradation of ZEB1 (REF. 54). Hence, EMT-TFs are controlled at 
multiple levels and by diverse upstream regulatory mechanisms, which cooperatively 
regulate activation of the EMT programme.
EMTs are known to have essential roles in embryogenesis, and the various EMT-TFs are 
specialized to orchestrate distinct steps of this process55. The associations of particular 
EMT-TFs with distinct embryogenic phases of development have been demonstrated most 
elegantly through gene-targeting studies in mice. Mice deficient in the Snai1 gene (encoding 
Snail) displayed the most severe phenotype observed to date in such studies: the embryos of 
these mice develop a morphologically abnormal mesodermal layer. More specifically, the 
cells within this layer fail to undergo EMT and retain their epithelial properties, resulting in 
the death of embryos at around embryonic day 8.5 (E8.5)56. Twist1-deficient and Zeb2-
deficient mouse embryos both exhibit failure of neural tube closure and die at around E11.5 
and E9.5, respectively57,58. Mice deficient for Snai2 (encoding Slug), Zeb1, Twist2, or Tcf3 
can survive to term, but have various severe developmental defects59-63. Hence, different 
EMT-TFs enable distinct processes in embryonic morphogenesis, indicating that they control 
different forms of the EMT programme.
While the mechanisms underlying EMT-programme activation are becoming increasingly 
clear, those responsible for the induction of the reverse process — MET — remain 
enigmatic. The prevailing hypothesis is that MET results simply from the deactivation of a 
previously active EMT programme, caused by reduced or fully absent expression of EMT-
TFs64,65; however, evidence also supports the presence of specific mechanisms that 
selectively activate the MET programme via pathways that do not directly involve the well-
characterized EMT-TFs. For example, the reprogramming of mouse fibroblasts into 
pluripotent stem cells involves MET-programme activation that is mediated, in part, by the 
induction of epithelial gene expression by the transcription factor KLF4 (REF. 66). 
Moreover, during kidney development in mice, Wnt9b secreted by the ureteric epithelium 
triggers the secretion of two other signalling proteins, Wnt4 and Fgf8, from pre-tubular 
aggregates; the latter two factors then contribute critically to the transition of these initially 
mesenchymal aggregates into the renal epithelium, in part, through the activation of the 
Lhx1 transcription factor67.
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EMT during carcinoma progression
In contrast to the general agreement on the contribution of EMTs to embryonic 
development, the involvement of this programme in carcinoma progression has been a 
matter of debate until very recently68. This controversy was largely attributable to scepticism 
raised by pathologists, who had not seen clear evidence of EMT in human carcinoma 
samples frequently enough to assert the wide involvement of the EMT programme in the 
pathogenesis of many cancer types69.
Indeed, the occurrence of a ‘complete EMT’, involving the loss of all epithelial traits and 
concomitant gain of the full spectrum of mesenchymal attributes (as seen in certain EMT 
processes during embryogenesis), is rare in human carcinomas. The exception to this rule 
derives from carcinosarcoma, a rare cancer type consisting of distinct epithelial 
(carcinomatous) and mesenchymal (sarcomatous) compartments that are derived from a 
common precursor-cell population70. The fact that the EMT programme in human 
carcinomas is usually activated only partially has probably obscured the detection of EMT 
markers in clinical carcinoma samples. The identification of EMT-programme components 
in islands of carcinoma cells has also been complicated by the presence of nearby stromal 
cells, which naturally display a diverse array of EMT-associated mesenchymal markers, 
confounding any clear association of EMT programmes specifically with the carcinoma 
cells.
Nonetheless, a rapidly growing number of studies are now adding to a large corpus of 
evidence for the activation of the EMT programme in, and its contributions to, the 
pathogenesis of human carcinomas. For more than 20 years, loss of expression of the 
adhesion protein E-cadherin in carcinoma cells has been recognized to be associated with 
metastasis and a poor prognosis71,72. More direct evidence of the relationship between the 
EMT programme and carcinoma progression was presented in the early 2000s, when the 
role of Snail as a driver of carcinoma progression was demonstrated. Specifically, expression 
of Snail in carcinoma cells was found to induce EMT in part via direct transcriptional 
repression of the gene encoding E-cadherin (CDH1)73. Moreover, Snail expression was 
detected in both invasive carcinoma cell lines and tumour specimens from patients with 
breast cancer, and the latter was found to correlate closely with histological dedifferentiation 
and the development of metastases74. A few years later, Twist1 was shown to be critical to 
the metastasis of mouse mammary carcinomas75. Results of a number of sub-sequent studies 
demonstrated correlations between the presence of EMT markers in many carcinoma types 
and poor patient prognoses, including, but not limited to, those with prostate, lung, 
pancreatic, liver, colorectal, or bladder carcinomas76-81.
The incomplete nature of the EMT programmes activated in human carcinomas — usually 
referred to as ‘partial EMT’ — could be inferred from early observations that loss of E-
cadherin expression, a hallmark of invasiveness in carcinomas, is usually partial71,72. More 
recently, an RNA in situ hybridization analysis of circulating tumour cells (CTCs) from 
women with breast cancer revealed the presence of cancer cells that concomitantly express 
epithelial and mesenchymal transcripts, and thus exhibit partial EMT activation82. 
Remarkably, these partial EMT cells were observed in samples from patients harbouring any 
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of the three major histological subtypes of invasive breast cancer (ER/PR-positive, HER2-
positive, or triple-negative), but not in non-neoplastic breast tissues. This partial activation of 
the EMT programme results in extensive phenotypic diversity of the carcinoma cells within 
individual tumours.
In addition to being activated partially, the EMT programme in human carcinomas is often 
activated reversibly, permitting the cancer cells to revert via MET programmes to epithelial 
states during the course of carcinoma progression (FIG. 2). Thus, in many different types of 
carcinomas, cancer cells at the invasive front of the primary tumour frequently exhibit signs 
of EMT activation, including the reduced expression of E-cadherin, while cells that follow 
behind usually display many epithelial traits and maintain extensive cell–cell adhesions83,84. 
This observation, together with the dynamic interconversions between the ‘leaders’ and the 
‘followers’ that have been shown to occur during the process of carcinoma invasion85, 
implies a plasticity of cell phenotypes and thus a reversibility of EMT programmes. Stated 
differently, carcinoma cells can flexibly activate EMT and MET programmes in the course 
of carcinoma invasion.
The behaviour of disseminated carcinoma cells that seed metastatic colonies is of great 
interest: founders of metastatic colonies, which are likely to have undergone an EMT before 
leaving the primary tumour, usually produce progeny at distant sites that regain theirrin86,87 
(FIG. 2). Moreover, studies in mouse models of breast or skin cancer have demonstrated that 
activation of the EMT programme in the primary tumour is crucial for the dissemination of 
tumour cells to the lungs, whereas the disseminated cells must subsequently undergo MET 
in order to efficiently form macroscopic metastases88,89. Gene-expression profiling of single 
cells from patient-derived xenograft (PDX) models of metastatic breast cancer has 
demonstrated that, before the formation of macroscopic metastases, disseminated tumour 
cells display stem-like transcriptional signatures, including the activation of the EMT 
programme; however, those in macroscopic colonies lose signs of EMT-programme 
activation and instead exhibit luminal-like, epithelial differentiation signatures90. Together, 
these observations indicate that the formation of macroscopic metastases usually involves 
inactivation of a previously active EMT programme in carcinoma cells.
How reversion of the EMT programme contributes mechanistically to the process of 
metastatic colonization remains to be resolved. In addition, restoration of the entire suite of 
epithelial traits is not necessary for the outgrowth of all types of metastases. Thus, in most 
cases of invasive lobular carcinoma of the breast, E-cadherin expression in the carcinoma 
cells is completely lost owing to CDH1 mutation91; however, these cancer cells frequently 
form macroscopic metastases in various organs. To summarize, although both clinical and 
pre-clinical observations clearly demonstrate that the EMT programme is regulated in a 
dynamic and reversible fashion during the progression of carcinomas, the functional 
significance of this reversibility awaits future study.
The timing of EMT-programme activation during the progression of carcinoma has been 
studied extensively using genetically-engineered mouse models, in which carcinoma cells 
were genetically labelled and thus could be distinguished from surrounding non-neoplastic 
cells. The findings revealed, intriguingly, that the EMT programme can be activated at pre-
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malignant stages of carcinoma development: in a breast cancer model driven by transgenic 
expression of a constitutively active mutant form of rat HER2, a high level of Twist1 
expression in mammary epithelial cells was detected at the stage of atypical ductal 
hyperplasia (ADH)92. Similarly, in another mouse breast cancer model, with transgenic 
expression of polyomavirus middle-T antigen (PyMT), Snail expression in mammary 
epithelial cells was observed at the ADH stage93. Moreover, in a pancreatic cancer model 
based on elimination of p53 expression and concomitant expression of the constitutively 
active G12D-mutated KRas, the pancreatic epithelial cells began to express Zeb1 at the stage 
of pancreatic intraepithelial neoplasia94. These results are consistent with clinical 
observations that systemic dissemination of tumour cells can start early in the disease course 
of certain types of carcinomas, including those of the breast and prostate95.
Together, these findings suggest that activation of an EMT programme and the resulting 
dissemination of pre-neoplastic cells can occur early in the multistep process of carcinoma 
progression; however, several key questions regarding the activation of the EMT programme 
early in carcinoma progression remain unanswered. For instance, the types of genetic 
alterations that predispose pre-malignant cells to activate previously silent EMT programmes 
are unknown. Moreover, whether and how disseminated preneoplastic cells with EMT-
programme activation contribute to the eventual formation of clinically detectable 
metastases is unclear96.
The activation of EMT programmes in carcinomas seems to be regulated not only 
temporally, but also spatially. As discussed, the dedifferentiation of epithelial tumour cells is 
particularly evident at the invasive fronts of carcinomas83,84, and data from genetically 
driven mouse models of carcinoma pathogenesis have reinforced the notion that the EMT 
programme is activated specifically at the invasive fronts of a tumour. In a breast cancer 
model with transgenic expression of the oncogenic transcription factor Myc, epithelium-
derived cells with mesenchymal-like morphological features (spindle shape, elongated 
nuclei, and poorly defined cell borders) were enriched at the interface between tumour and 
stromal tissues97. Moreover, in a pancreatic cancer model, elevated expression of Zeb1 in 
the carcinoma cells was found to be evident particularly at the periphery of the tumour 
tissue, where abundant inflammatory cells accumulated94. The commonalities in both spatial 
and temporal patterns of EMT, observed among multiple carcinoma types in both humans 
and mice, indicate that EMT-programme activation is a highly regulated process, which is 
strongly influenced by contextual signals that individual carcinoma cells experience at 
various locations within a tumour.
Microenvironmental regulation of EMT
A large body of evidence points to the critical contributions made by resident and recruited 
non-neoplastic cell types within the tumour stroma to the regulation of carcinoma cell 
behaviours. These stromal cells can be categorized into three major classes: angiogenic 
vascular cells, infiltrating immune cells, and carcinoma-associated fibroblasts (CAFs)98.
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The role of carcinoma-associated fibroblasts
CAFs have been reported to arise from multiple sources, including tissue-resident 
fibroblasts, mesenchymal stem cells, stellate cells, and endothelial cells; a distinct profile of 
secreted signalling molecules distinguishes CAFs from non-neoplastic tissue fibroblasts. At 
a biological level, CAFs display an ‘activated’ phenotype, reminiscent of that observed in 
cells actively participating in wound healing. Moreover, the classification of CAFs can 
substantially overlap with myofibroblasts that are abundant in the stroma of many high-
grade carcinomas as well as in areas of active inflammation99,100. Although the precise 
molecular definition of this apparently heterogeneous collection of cells remains a matter of 
debate, a growing body of evidence supports the important role of CAFs in carcinoma 
progression101. Indeed, CAFs are particularly well characterized with respect to their 
involvement in EMT-programme activation in carcinoma cells (FIG. 3a).
Intriguingly, the admixture of CAFs isolated from prostate cancer tissue enabled 
immortalized, but not transformed, human benign prostatic hyperplasia epithelial (BPH-1) 
cells to form tumours in athymic nude mice, whereas fibroblasts isolated from the 
corresponding non-neoplastic prostatic tissue did not102. Some of the resulting tumour cells 
had reduced E-cadherin expression and elevated vimentin expression, indicating the 
induction of EMT in BPH-1 cells by the co-inoculated CAFs, which might at least partially 
explain the increased tumour-initiating potential observed102,103.
Several subsequent reports identified potential mechanisms by which CAFs activate the 
EMT programme in nearby carcinoma cells. CAFs from human prostate cancers induced 
EMT in co-cultured PC-3 human prostate carcinoma cells via secretion of matrix metallo-
proteinases (MMPs)104. In addition, the conditioned culture medium of CAFs isolated from 
invasive breast tumours induces EMT-like changes in multiple human breast cancer cell 
lines; this effect has largely been attributed to TGFβ secreted at high levels by CAFs105. 
Finally, CAFs have been shown to be enriched at the invasive fronts of multiple types of 
human carcinoma106-108, suggesting that signals arising from bidirectional interactions 
between carcinoma cell and CAFs account for the spatial patterns of EMT activation 
described previously.
The influence of inflammation
Several conditions specific to the tumour microenvironment seem to contribute to the 
activation of the EMT programme in carcinoma cells. Among these conditions, tissue 
inflammation comprises a pervasive and critical component of the tumour 
microenvironment. Diverse lines of evidence suggest that inflammation contributes to at 
least two stages of carcinoma pathogenesis. First, chronically inflamed tissues are fertile 
sites for the initiation of carcinomas. Thereafter, established carcinomas can undergo 
histopathological progression to states of high-grade malignancy, such as those associated 
with expression of EMT programmes, under the influence of inflammation-associated 
signals (FIG. 3b). Indeed, in this second stage involving established malignant tumours, 
inflammatory cells and soluble mediators of inflammation, such as cytokines and 
chemokines, are abundant within the tumour microenvironment. Thus, the RAS 
oncoproteins, products of the most frequently mutated oncogenes in human cancers, have 
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been demonstrated to induce cancer cells to produce proinflammatory cytokines and 
chemokines, such as IL-8 and the CXCL1 (REFS 109,110). The resulting RAS-induced 
inflammatory tumour microenvironment contributes reciprocally to disease progression 
through several distinct mechanisms, including EMT-programme activation109,111.
Studies have highlighted the contribution of specific cytokines released by tumour-
associated inflammatory cells to the activation of the EMT programme. TNFα treatment 
resulted in NF-κB-dependent stabilization of the otherwise unstable Snail protein in multiple 
human cancer cell lines, thereby activating EMT, which in turn increased tumour-cell 
invasiveness and dissemination to distant sites in preclinical models112. Other prototypic 
proinflammatory cytokines, including IL-1β and IL-6, have also been demonstrated to 
activate the EMT programme in carcinoma cells113,114. These observations provide a 
mechanistic link between tissue inflammation, heterotypic signalling, and activation of EMT 
programmes in carcinoma cells.
The contributions of cellular components of inflammation, such as macrophages, 
neutrophils, and myeloid-derived suppressor cells (MDSCs), to cancer progression have 
been studied extensively. Experiments in mice that lack expression of the key macrophage-
lineage cytokine Csf1 and therefore lack functional macrophages have revealed that these 
cells are dispensable for the initiation and subsequent growth of PyMT-driven primary 
mammary carcinomas, but are critical to the formation of lung metastases from these 
tumours115. Moreover, close negative correlations between the abundance of tumour-
associated macrophages (TAMs) and patient prognosis have been reported for multiple 
cancer types, including lung, breast, prostate, and ovarian cancers116.
Analyses of the mechanisms underlying promotion of carcinoma progression have 
demonstrated that TAMs, like CAFs, can contribute to the activation of EMT programmes in 
carcinoma cells. Thus, depletion of macrophages from mice bearing F9 teratocarcinoma 
allo-grafts results in the epithelial differentiation of tumour cells, thus indicating the critical 
role of macrophages in maintaining the mesenchymal properties of the tumour cells. This 
EMT effect is mediated, in part, by the secretion of TGFβ by macrophages117. Moreover, 
activated macrophages induce EMT in MCF7 human breast cancer cells following co-
culture in vitro or co-implantation to form xenograft tumours in vivo; this effect is 
attributable, in part, to secretion of the chemokine CCL18 by macrophages118.
In addition, critical roles of neutrophils and MDSCs in the establishment, growth, and 
progression of various cancer types have been documented119,120. Intriguingly, such pro-
tumour effects of these cells are also attributable, in part, to their capacity for activating 
EMT programmes within neighbouring cancer cells121,122. Hence, various secreted proteins 
and host cell types present in the inflammatory tumour microenvironment contribute, 
perhaps in a coordinated fashion, to the induction of EMT in carcinoma cells.
The effects of hypoxia
Hypoxia, which is often present in poorly vascularized regions of carcinomas, can also 
contribute to activation of the EMT programme (FIG. 3c). A direct connection between 
HIF-1 — a central transcriptional regulator of cellular responses to hypoxia — and the EMT 
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of carcinoma cells has been demonstrated in the case of clear-cell renal-cell carcinoma 
(RCC), a disease in which frequent loss-of-function of the von Hippel-Lindau (VHL) 
tumour-suppressor protein results in the constitutive activation of HIF-1. In this context, 
HIF-1 represses the expression of E-cadherin indirectly by inducing the expression of ZEB1, 
ZEB2, and TCF3, thereby conferring mesenchymal attributes on the carcinoma cells123,124. 
In addition, multiple human carcinoma cell lines undergo EMT upon exposure to hypoxia in 
vitro, via a mechanism that is dependent, in part, on HIF-1 activation125-127. Notably, direct 
activation of the TWIST1 promoter by HIF-1 has also been demonstrated127. Hence, 
multiple distinct components of the tumour microenvironment and physiological conditions 
contribute to the activation of the EMT programme in carcinoma cells via diverse 
mechanisms. This complexity creates a serious challenge to the formulation of therapeutic 
strategies designed to effectively target the EMT programme.
The relationship between EMT and CSCs
The EMT programme has been portrayed for two decades as a major mechanism underlying 
carcinoma-cell invasion from the primary tumour mass into the surrounding stroma — the 
very first step of the complex series of events that lead to the formation of metastases128. 
This invasion step is followed by the entrance of cancer cells into the circulation 
(intravasation); transportation in the blood to the capillary beds of distant organs, where they 
become physically trapped; escape from capillary lumina to the tissue parenchyma 
(extravasation); and, ultimately, the outgrowth of these micrometastases into macroscopic 
metastases in the foreign tissue (colonization). These various processes, together, are often 
termed the ‘invasion-metastasis cascade’ (REF. 129). The scope of biological processes 
driven by the EMT programme, however, has been expanded far beyond the initial step of 
carcinoma-cell invasion, owing to the observation that experimental activation of EMT, via 
either the over-expression of Twist1 or Snail EMT-TFs, or treatment with TGFβ, confers 
many of the properties of CSCs on otherwise epithelial carcinoma cells27,31. These include 
CSC-specific cell-surface marker expression — that is, elevated and reduced expression of 
CD44 and CD24 glycoproteins, respectively, an increased ability to form spheres in a 
suspension culture, and an enhanced ability to seed tumours in mice. These observations, 
together with those from a series of follow-up studies, have now demonstrated that activation 
of the EMT programme in neoplastic cells is closely linked to entrance into the CSC state, 
across a wide variety of human carcinoma types, revealing multifaceted effects of the EMT 
programme in driving the malignant phenotype of carcinoma cells130 — and bringing this 
developmental programme to the heart of cancer biology (TABLE 1).
The association between the EMT programme and the CSC state indicates that the activation 
of this programme in non-CSCs enables their conversion into CSCs. In addition, CSCs, by 
definition, should have the ability to differentiate into non-CSCs, triggered presumably by 
the activation of the MET programme. These assumptions, taken together with the 
aforementioned reversibility of EMT and MET in carcinoma cells, suggest the involvement 
of substantial phenotypic plasticity, enabling these cells to transition back-and-forth between 
the CSC and non-CSC states.
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Indeed, tumour cells in the non-CSC subpopulation can spontaneously undergo EMT-like 
changes and acquire CSC-like cell-surface marker expression, as well as an enhanced 
capacity to seed tumours in mice131. A similar dedifferentiation of non-CSCs to CSCs has 
also been observed in multiple experimental systems132,133, indicating that the 
unidirectional stem-cell hierarchy operating in non-neoplastic tissues — whereby only stem 
cells can repopulate the entire cell population of a differentiated, functional adult tissue, but 
not the reverse — does not apply to neoplastic tissues. Moreover, given their observed 
plasticity, carcinoma cells might interconvert between multiple alternative states 
characterized by different degrees of mesenchymal features, one of which comprises CSCs. 
Such behaviour implies that EMT-induced non-CSC-to-CSC conversion should be 
considered simply as a phenotypic shift within a range of fluctuation, rather than true 
dedifferentiation. This plasticity of the CSC programme also points to the importance of 
further characterizing the differences between the stem-cell programmes of non-neoplastic 
tissues and those of neoplastic tissues, as this understanding will be critical to designing 
therapeutic strategies to selectively target CSCs without damaging non-neoplastic tissue 
stem cells.
EMT, CSCs, and metastasis
Given their unique property of being able to seed new tumours, CSCs — but not non-CSCs 
— should be capable of founding metastatic colonies after disseminating to foreign 
tissues134. This logic, when taken together with the aforementioned EMT–CSC connection, 
indicates that EMT-programme activation is necessary not only for the physical 
dissemination of carcinoma cells to distant tissues, but also for entrance into the CSC state 
that enables the disseminated cells to serve as founders of metastatic colonies and, thus, to 
succeed in colonizing foreign tissues. Indeed, activation of the EMT programme in 
carcinoma cells results in the formation of larger numbers of macroscopic lung metastases in 
mice, even when these cells are injected directly into the venous circulation, thereby 
bypassing the earlier steps of the invasion-metastasis cascade127,135,136. Moreover, as 
mentioned previously, disseminated carcinoma cells often exhibit signs of activation of the 
EMT programme before the formation of macrometastases90,137. These observations 
reinforce the notion that EMT-programme activation enables carcinoma cells to serve as 
founders of metastatic colonies.
More recently, while attempting to elucidate the molecular interactions of carcinoma cells 
infiltrating the lung parenchyma with ECM proteins, we and others discovered that CSC-like 
cells with high metastasis-seeding abilities develop mature adhesion plaques — 
macromolecular structures composed of clustered integrins — far more abundantly than do 
the related, poorly metastasis-seeding and thus non-CSC-like cells138,139. These mature 
adhesion plaques contribute functionally to the differing powers of metastasis seeding 
between these cell types, by enabling potent activation of focal adhesion kinase (FAK), the 
activity of which is critical to the initial proliferation of CSC-like cells within the lung 
tissue140,141. Further exploration revealed the mechanistic basis for the differing capabilities 
of CSC-like cells that have activated an EMT programme and non-CSC-like cells that have 
not done so to form mature adhesion plaques: this difference is attributable, in part, to the 
distinct potentials of these cell types, following their extravasation, to extend actin-rich, 
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integrin-presenting protrusions141. These protrusions, which we named ‘filopodium-like 
protrusions’ (FLPs), are abundantly formed only by the EMT-activated cells; following 
formation of integrin–ECM connections, the FLPs contribute to the development of mature 
adhesion plaques, thereby enabling the potent activation of FAK signalling141. Intriguingly, 
in multiple carcinoma cell types, experimental activation of the EMT programme results in a 
remarkable increase in the ability of these cells to extend FLPs141. This ability, in turn, 
permits these EMT-activated cells to proliferate following extravasation, ultimately enabling 
them to seed metastases efficiently. This chain of causality provides one explanation for the 
link between the EMT programme and the enhanced metastasis-seeding ability of carcinoma 
cells (FIG. 4a).
In truth, this depiction might oversimplify the complexity of the final, post-extravasation 
steps of metastasis formation: the EMT programme might enable physical dissemination of 
carcinoma cells to distant tissues and also confer on them an ability to initiate metastatic 
growths, but is unlikely to solve an additional and critical obstacle confronting these cells. 
This hurdle involves the adaptation of cells originating in one tissue to the microenvironment 
of a second, unfamiliar tissue. Most carcinoma cells are hypothesized to be poorly adapted 
to grow in foreign tissues, at least initially, and must contrive adaptive programmes in order 
to continue to expand. These adaptations are likely to be accompanied by, as mentioned, the 
reversion of the EMT programme (or activation of a MET programme) in carcinoma cells, 
and indeed robustly growing metastatic colonies are usually composed mostly of carcinoma 
cells that have regained their epithelial attributes86,87.
In contrast to the prevailing view that the EMT programme contributes critically to cancer 
metastasis, two reports have presented evidence of the contrary. In one of these studies, a 
linage-tracing approach was used to follow the fate of tumour cells that have expressed the 
EMT markers, S100A4 (also known as fibroblast-specific protein 1) and vimentin, and 
demonstrated that lung metastases in the PyMT-driven mouse mammary carcinoma model 
are formed predominantly by cells that have not previously expressed these markers142. In 
the other study, pancreas-specific deletion of either Snai1 or Twist1 was found to have no 
substantial effect on metastasis formation in a mouse model of pancreatic ductal 
adenocarcinoma143. These studies have raised questions regarding the ubiquitous 
requirement for EMT in cancer metastases, although the observations made therein need to 
be interpreted with caution. As discussed previously, the EMT programme is usually 
activated only partially in carcinoma cells, resulting in aggressive cells that might not be 
fully mesenchymal and, thus, might not express the two markers specific for highly 
mesenchymal cells, S100A4 and vimentin. Moreover, given their extensively overlapping 
functions, the effects of genetic elimination of a single EMT-TF are likely to be masked by 
the compensatory upregulation of others.
The molecular mechanism behind the EMT–CSC link
The connection between EMT and CSC status is now supported by substantial experimental 
evidence; however, the mechanistic link between these two phenotypes remains largely 
elusive. One of the potential explanations for this link is that alterations in the spectrum of 
secreted proteins (that is, the ‘secretome’) of carcinoma cells induced by the EMT 
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programme establish autocrine signalling loops, which in turn are essential for the induction 
and maintenance of stem-cell properties. Indeed, results of a study analysing the secretome 
of transformed HMLER human mammary epithelial cells have revealed that the activation of 
the EMT programme induces autocrine signalling loops that are known to contribute 
critically to the ‘stemness’ of non-neoplastic and neoplastic cells; these include the TGFβ –
SMAD and Wnt–β-catenin pathways144 (FIG. 4b). Consistent with this notion, the blockade 
of these auto-crine signalling loops is sufficient to prevent the acquisition of CSC properties 
by the HMLER cells following experimental activation of the EMT programme.
The EMT programme also seems to contribute to CSC phenotype through its effects on 
intracellular signalling pathways. For example, Snail has been reported to reduce the 
expression of the tumour-suppressor protein p53 in carcinoma cells via formation of a Snail–
histone deacetylase 1 (HDAC1)–p53 ternary complex and subsequent deacetylation of p53, 
thereby promoting its protea-somal degradation145. Importantly, the tumour-initiating ability 
of neoplastic cells in the PyMT-driven mouse mammary tumour model is diminished by 
deletion of Snai1, and this ability can be restored through concomitant deletion of Tp53 
(encoding p53)145. Hence, the EMT programme seems to confer CSC phenotypes on 
carcinoma cells through effects on both the extracellular and intracellular signalling 
machinery.
The importance of the EMT programme in driving the CSC phenotype itself requires further 
investigation. Indeed, whether activation of the EMT programme is necessary and/or 
sufficient for the acquisition of the CSC phenotype across various carcinoma types remains 
to be determined. In breast cancer, CSCs are demonstrated to be present in two alternative 
phenotypic states, namely, epithelial-like and mesenchymal-like, and cells in either state are 
capable of seeding tumours in mice146,147. Moreover, although the activation of the EMT 
programme markedly increases the tumour-initiating ability of carcinoma cells in many 
model systems, excessive activation of this programme is found to be detrimental for tumour 
initiation (FIG. 1b). This finding explains why increasing attention is being placed on the 
‘partial EMT’ state, which seems to be critical for the maximal tumorigenic activity of 
CSCs148. More specifically, in a model of claudin-low breast cancer, in which most 
carcinoma cells display a highly mesenchymal phenotype, a subpopulation of cells with 
relatively epithelial characteristics exhibited greater tumorigenic activity than the bulk 
population of the cells149. Together, these observations indicate that the contribution of the 
EMT programme to the CSC phenotype is variable, most likely depending on cell type 
and/or coexisting genetic/epigenetic abnormalities. This variability underscores the 
complexity of the genetic/epigenetic mechanisms driving the CSC phenotype in carcinoma 
cells, an understanding of which will likely be critical to the future development of novel 
therapies directed against the (partially) mesenchymal cells in human carcinomas, including 
their subpopulations of CSCs.
EMT and therapeutic resistance
Soon after the introduction of the CSC concept, some researchers postulated that CSCs are 
more resistant than non-CSCs within the same tumours to elimination following 
conventional chemotherapy and radiotherapy12,150. This idea originated, at least in part, 
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from early observations indicating that non-neoplastic tissue stem cells exhibit higher levels 
of resistance to chemotherapeutic agents than that of the differentiated cell types within the 
same tissues151. This resistance has been attributed to various mechanisms, including: 
elevated expression of antiapoptotic proteins; increased levels of ATP-binding cassette 
(ABC) transporters, transmembrane protein transporters that are known to mediate drug 
efflux and, thus, to confer multidrug resistance on cancer cells152-155; and the slow 
proliferation rate of stem cells156.
More recently, technical advances in the identification and isolation of CSC-enriched 
subpopulations of cells from various tumours types have made assessment of the relative 
sensitivity of CSCs and non-CSCs to therapeutic agents possible. These analyses have 
revealed, as anticipated, that chemotherapy and/or radiotherapy successfully eliminate the 
bulk population of non-CSCs, while leaving behind considerable numbers of CSCs in 
multiple cancer types, in both preclinical and clinical samples21,157,158. In addition, the 
survival of CSCs following certain kinds of molecularly targeted treatment and 
immunotherapy is greater than that of non-CSCs. For instance, the CSC-enriched 
subpopulation of chronic myeloid leukaemia (CML) cells was found to be far more resistant 
to treatment with the BCR–ABL1 kinase inhibitor imatinib than was the CSC-deprived 
subpopulation of the CML cells from the same patients159. In addition, in a mouse model of 
prostate cancer, therapeutic vaccination using a cDNA library derived from non-neoplastic 
prostate tissue results in the initial regression of the tumour followed by the recurrence of a 
more aggressive tumour composed of tumour cells with a much higher tumour-initiating 
ability than those of the original tumour160,161.
Nonetheless, further understanding of the connection between CSCs and therapeutic 
resistance had been hampered by the lack of reliable markers to identify cell populations 
highly enriched with CSCs, and by an insufficient understanding of the mechanisms that 
govern the phenotype of CSCs. In fact, the sets of markers used to identify cancer cell 
populations enriched for CSCs are being continuously updated, leaving room for further 
improvement. These difficulties greatly complicate attempts to predict the therapeutic 
resistance of ‘pure’ populations of CSCs. Nonetheless, the identification of the EMT 
programme as a common regulator of the CSC phenotype across various carcinoma types 
has provided us with an experimental opportunity to investigate, at the molecular level, how 
CSCs and therapeutic resistance are linked via EMT programmes (FIG. 5; TABLE 2).
Analyses of the relationships between gene-expression profiles of tumour samples and the 
clinical responses of the patients from which they were obtained have resulted in the 
identification of a strong correlation between an EMT-associated gene-expression signature 
and treatment resistance. For instance, an analysis of responses to chemotherapy in a large 
cohort of patients with breast cancer revealed a close association between therapeutic 
resistance and increased expression of genes that are usually expressed primarily by the 
stromal cells; this transcriptional upregulation seems to be caused, in part, by activation of 
the EMT programme within carcinoma cells162. In addition, findings of a study designed to 
interrelate gene-expression profiles and responses to EGFR or PI3K inhibitors in clinical 
samples and in various cell lines derived from patients with non-small-cell lung carcinoma 
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(NSCLC) have also identified a 76-gene EMT signature as a robust predictor of clinical 
resistance to these agents163.
Collectively, these observations strongly support the notion that the EMT programme 
contributes critically to the development of resistance to various types of therapeutic agents 
in multiple cancer types; they also illustrate how the identification of the functional link 
between the EMT programme and the CSC phenotype has enabled us to understand at the 
molecular level the otherwise enigmatic phenomenon concerning the resistance of CSCs to 
multiple therapeutic modalities. Further study of the connections between the EMT 
programme, the CSC phenotype, and therapeutic resistance will certainly be required for the 
development of more effective treatment strategies to eradicate CSCs.
Targeting the EMT programme for therapy
The development of treatment strategies to directly target the EMT programme is both 
reasonable and promising, given the emerging importance of this programme in the 
malignant progression of carcinomas, as well as the frequent acquisition of therapeutic 
resistance by carcinoma cells. At least three different approaches might be pursued: 
preventing the induction of EMT; selectively targeting cells that have active components of 
an EMT programme; and/or reversing the process of EMT by forcing more-mesenchymal 
carcinoma cells to revert to an epithelial state via activation of the MET programme.
Prevention of EMT induction
EMTs can be prevented by interfering with the signalling processes that are critical to the 
activation and subsequent maintenance of EMT programmes. TGFβ signalling is among the 
best-characterized pathways involved in EMT induction; however, this cytokine has 
multifaceted effects on cancer cells and, therefore, attempts at the therapeutic inhibition of 
this pathway require caution. Specifically, although TGFβ potently promotes the progression 
of the tumours via mechanisms including the activation of the EMT programme and 
resulting invasion of carcinoma cells into the surrounding non-neoplastic tissue, it also 
negatively controls the initial stages of tumour formation through its antiproliferative 
effects164,165. Indeed, SKI and the SKI-like protein SnoN, endogenous inhibitors of TGFβ 
signalling, are known oncoproteins; increased expression of these proteins has been 
associated with the development of many types of human cancers, including melanoma and 
oesophageal cancer166. Hence, inhibition of TGFβ signalling might actually be 
counterproductive by promoting carcinoma-cell proliferation in the early stages of the 
disease. In addition, TGFβ signalling has critical roles in controlling the behaviours of 
stromal and immune cells, making it difficult to specifically target the process of TGFβ-
mediated induction of EMT in the cancer cells. Nevertheless, inhibitors targeting this 
signalling pathway are currently undergoing both preclinical and clinical testing167,168; 
owing to the complex and multifaceted effects of TGFβ signalling, appropriate stratification 
of the patients and optimization of drug-administration protocols will be critical to the 
effective use of these inhibitors.
Other potential therapeutic targets for preventing the induction of EMT include hepatocyte 
growth factor (HGF)–HGF receptor (HGFR; a proto-oncogene also known, confusingly, as 
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MET) signalling. Besides promoting cell proliferation, HGF–HGFR signalling also activates 
the EMT programme and induces cell motility169,170. This pathway contributes critically to 
cancer pathogenesis, as exemplified by its frequent activation, often by point mutation or 
amplification of the HGFR gene (MET), in many cancer types. Thus, HGF–HGFR 
signalling is a promising target of anticancer therapy, and substantial efforts have been made 
to develop antagonists of this pathway. In particular, a number of small-molecule inhibitors 
of the enzymatic activity of the HGFR tyrosine-kinase domain are being evaluated in clinical 
trials. Of note, two multikinase inhibitors with activity against this protein are already 
approved by the FDA: crizotinib, for the treatment of NSCLC; and cabozantinib, for the 
treatment of medullary thyroid cancer and RCC171. However, the extent to which HGFR 
inhibition contributes to the antitumour activity of these agents in these indications remains 
to be clarified.
In principle, blockade of EMT could also be accomplished by targeting the components of 
the tumour microenvironment that contribute to the activation of the EMT programme in 
carcinoma cells. Possible treatment strategies along this line include suppression of tumour-
associated inflammation and hypoxia, as well as targeting of specific types of host cells, 
such as CAFs or TAMs172,173. As discussed, however, the manner in which each of these 
microenvironmental components triggers activation of the EMT programme in nearby 
carcinoma cells remains under investigation; a more detailed understanding of these 
mechanisms will be necessary in order to manipulate the microenvironmental factors in 
ways that will block EMT-programme activation.
Selective targeting of cells that have undergone EMT
Substantial efforts have been made to selectively target cancer cells that have undergone 
EMT, starting with attempts to therapeutically block the functions of classic EMT-associated 
markers. For instance, the natural compound withaferin A binds to, among other things, 
vimentin intermediate filaments, a standard marker of EMT, ultimately causing the 
degradation of these filaments174. Withaferin A treatment has been demonstrated to block 
the in vitro invasion and in vivo metastasis formation by breast cancer cells175, and is, 
therefore, an attractive target for further development as a therapeutic anticancer agent. In 
addition, treatment with monoclonal antibodies against the ectodomain of N-cadherin, 
another important marker of EMT, had the same effects on multiple prostate cancer cell 
lines176. The therapeutic index of both agents, however, remains to be examined in depth. 
Potential complications might plausibly arise from the fact that these mesenchymal markers 
are widely expressed by non-neoplastic mesenchymal cells, such as fibroblasts, resulting in 
on-target, off-tumour toxicities.
Defining and interfering with signalling pathways that contribute critically to the behaviours 
of carcinoma cells that have undergone EMT is another potential approach to anticancer 
therapy. One study along this line has identified AXL, a receptor tyrosine kinase activated by 
the GAS6 ligand, as a signalling protein whose expression and function are linked tightly 
with expression of an EMT signature163,177. The expression of AXL is strongly induced by 
the experimental activation of the EMT programme in the immortalized MCF10A human 
mammary epithelial cell line178. In addition, short hairpin RNA (shRNA)-mediated 
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knockdown of AXL expression attenuates in vitro invasion as well as in vivo tumour 
initiation and metastasis formation by multiple mesenchymal-like breast cancer cell lines178. 
Similarly, in the aforementioned study that identified a strong correlation between the EMT-
associated gene-expression signature and resistance to EGFR or PI3K inhibitors in NSCLC, 
the expression of an EMT-associated signature was closely accompanied by the elevated 
expression of AXL and its ligand, GAS6. Intriguingly, the combination of the EGFR 
inhibitor erlotinib and the AXL inhibitor SGI-7079 successfully overcame the resistance of 
mesenchymal-like NSCLC cells to erlotinib treatment in a mouse xenograft model163. 
Together, these experimental observations identify AXL as a critical mediator of EMT-
associated phenotypes in cancer cells, including CSC-like properties, which suggests a 
strong potential of this receptor as a therapeutic target for the selective elimination of CSCs 
with an active EMT programme. The first AXL-specific small-molecule inhibitor, BGB324, 
entered clinical trials in 2013 (REF. 179). An initial clinical study in NSCLC has 
demonstrated that BGB324 can be safely administered to patients and a proportion of 
patients achieve durable disease stabilization for at least 6 months180.
High-throughput screening approaches have been used to identify therapeutic vulnerabilities 
in carcinoma cells that have an active EMT programme and thus have entered a CSC state. 
For example, a chemical compound screen of cells from the immortalized HMLE human 
mammary epithelial cell line, with or without prior experimental activation of the EMT 
programme, resulted in the identification of the potassium ionophore salinomycin as an 
agent with cytotoxic activity specifically in cells that have undergone EMT181. Findings of 
an analogous screen for kinase inhibitors demonstrated that inhibitors targeting PKCa 
selectively eliminate HMLE cells with an active EMT programme182. In both cases, the 
clinical utility of these and similar agents for targeting CSCs with active EMT programmes 
requires extensive testing and validation.
Reversing the process of EMT
From a therapeutic standpoint, reversing the process of EMT — inducing MET — would be 
beneficial, considering the critical contribution of the EMT programme to multiple 
malignant traits of cancer. By doing so, cancer cells in the CSC state with an active EMT 
programme will be forced to differentiate into non-CSCs and regain epithelial traits, thereby 
losing both enhanced tumorigenic activity and resistance to various therapeutic agents. This 
strategy is reminiscent of differentiation therapy used in patients with acute promyelocytic 
leukaemia (APL), whereby treatment with all-trans retinoic acid (ATRA) induces terminal 
differentiation of leukaemic promyelocytes, eventually leading to apoptotic death. ATRA is 
a component of the first-line treatment of APL and its use has dramatically improved the 
prognosis of patients with this disease183.
As reported in 2016, a screen for agents that reactivate the promoter of the E-cadherin gene 
(CDH1) in mesenchymal cells identified cholera toxin and forsko-lin, both of which increase 
intracellular levels of cyclic AMP and thereby enhance signalling through protein kinase A 
(PKA)184. Treatment of the spontaneously arising mesenchymal derivatives of HMLE cells 
with either of these two agents, or forced expression of a constitutively active PKA mutant, 
resulted in the induction of MET and associated reductions in invasiveness and sphere-
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forming potential184. Interestingly, this MET was accompanied by sensitization of these 
cells to therapeutic agents that included doxorubicin, paclitaxel, proteasome inhibitors, and 
EGFR inhibitors184. Additional studies will be needed to assess the general applicability and 
clinical utility of these findings. In particular, given the aforementioned requirement for 
reversion of the EMT programme at the last step of the invasion–metastasis cascade, 
therapeutic activation of the MET programme might adversely promote metastatic colony 
formation. Thus, the timing and strategy of MET-programme activation will need to be 
determined carefully, as a prerequisite to the success of this therapeutic approach. 
Nonetheless, such ‘differentiation therapy’ is an attractive avenue for the development of 
novel anticancer drugs.
Conclusions
Advances in basic and translational cancer biology have enabled us to understand, in 
unprecedented detail, the actions and the outcomes of cancer therapies. In particular, major 
conceptual advances, including the introduction of the CSC concept and elucidation of the 
connection between the EMT programme and the CSC state, have provided us with new 
insights into clinically significant problems, such as the development of resistance to 
therapy. Conventional therapeutics usually eliminate the bulk non-CSC population while 
sparing the minor subpopulations of CSCs, thereby leaving open the possibility of future 
local disease recurrence and/or the development of metastases17,185. Moreover, EMT seems 
to be a major strategy used by carcinoma cells to acquire a CSC phenotype, making this 
programme an attractive novel target for cancer therapy24. Indeed, therapeutic strategies 
based on this new knowledge are currently being designed and tested, and will probably 
result in improvements in cancer therapy in the near future186.
Nevertheless, the deduction that activation of the EMT programme in carcinoma cells 
generates CSCs has been challenged by more recent findings. Thus, while EMT-programme 
activation in the otherwise-epithelial carcinoma cells generally results in an enhanced 
potential for tumorigenesis, full activation of the entire EMT programme — that is, complete 
transition to a mesenchymal cell type — has been found to be detrimental to tumorigenic 
activity88,148,187. Moreover, under certain conditions, CSCs can undergo phenotypic drift, 
thus losing mesenchymal traits while maintaining their tumorigenic activity146,147. Such 
observations indicated that the EMT programme and the CSC phenotype are closely 
associated, but can actually be uncoupled from one another under certain conditions. Further 
investigation of the association and distinction between EMT and the CSC state will be 
required in order to exploit the EMT–CSC link for the improvement of therapeutic practice.
Another important challenge related to EMT–CSC connection derives from the phenotypic 
plasticity of non-CSCs. Unlike their counterparts in non-neoplastic tissues (that is, 
terminally differentiated cells), non-CSCs in the tumour tissue can spontaneously undergo 
EMT and dedifferentiate into new CSCs, thereby regenerating tumorigenic potential188. 
Hence, initial eradication of CSCs alone will probably not preclude disease recurrence; 
consideration of the simultaneous targeting of CSCs and non-CSCs, as well as a better 
understanding of the process of dedifferentiation of non-CSCs, will be critical to the 
development of effective anticancer therapies.
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Research advances have provided solid evidence for the connection between the activation 
of the EMT programme and the development by carcinoma cells of resistance to 
therapeutics, not only in the experimental models, but also in clinical settings. Indeed, 
residual carcinoma cells surviving after various types of therapy, including chemotherapy, 
molecularly targeted therapy, and immunotherapy, commonly display signs of EMT 
activation. Thus, the efficiency of these therapeutic modalities in generating durable clinical 
responses might be improved substantially by targeting cancer cells that have activated 
portions of the EMT programme. However, the mechanisms accounting for the maintenance 
and/or induction of the EMT programme in these residual carcinoma cells remain largely 
obscure. EMT in carcinoma cells seems to be governed by highly complex and redundant 
mechanisms, posing a serious challenge to the selective and truly effective targeting of this 
programme. Overcoming these difficulties will enable us to design treatment strategies that 
have a minimal risk of developing resistance, ultimately paving the way to curative 
treatments of cancer. Finally, as is apparent from the present discussions, many of the 
biological traits of cancer cells are dictated by non-genetic mechanisms, revealing the limits 
of cancer genome sequencing in providing insights into many aspects of cancer cell biology 
and necessitating the integrated use of complementary approaches, such as epigenomics and 
transcriptomics.
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Key points
• The cancer stem cell (CSC) concept posits that a subpopulation of neoplastic 
cells with stem-cell properties — particularly the capacity to self-renew and 
give rise to various more differentiated cell types — lies at the apex of a 
tumour cell hierarchy and serves as a critical driver of tumour progression
• The phenotypic differences between CSCs and the bulk tumour cells that lack 
‘stemness’ (that is, non-CSCs) seem to be attributable predominantly to 
epigenetic changes caused by the activation of a epithelial-to-mesenchymal 
transition (EMT) programme in the former
• Thus, the CSC paradigm provides an explanation for how epigenetic 
mechanisms can drive the phenotypic diversity of neoplastic cells — an 
attribute critical for the development of resistance to therapy
• Indeed, most conventional therapeutics are inefficient in eradicating 
carcinoma cells that have entered the CSC state via activation of the EMT 
programme, thereby permitting CSC-dependent disease relapse
• Targeting the EMT programme in order to eliminate CSCs offers a promising 
avenue for the improvement of cancer therapy; however, the success of this 
approach will require an increase in our mechanistic understanding of the 
EMT–CSC link
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Figure 1. Morphological and physiological changes associated with the epithelial-to-
mesenchymal transition (EMT)
a ∣ A schematic overview of EMT-associated changes in cell physiology. Activation of the 
EMT programme induces profound changes in various aspects of cell morphology and 
physiology, most notably in cell cell junctions, cytoskeletal composition, cellular 
interactions with the extracellular matrix (ECM), and cell polarity. b ∣ Summary of the 
physiological outcomes of EMT in carcinoma: the profile of the shapes illustrates how the 
extent of invasiveness, the tumour-initiating ability, and degree of drug resistance change 
across the spectrum of EMT-programme activation. Carcinoma cells invade surrounding 
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tissues either by individual-cell migration or multicellular migration (as cell cohorts). In 
general, migration of individual cells, which requires the strong activation of the EMT 
programme, results in faster tissue invasion than occurs by multicellular migration, the mode 
of migration that predominates when the EMT programme is only weakly activated189. The 
tumour-initiating ability of carcinoma cells is also affected by the level of EMT-programme 
activation, peaking at an intermediate level of EMT in these cells; extensive EMT activation 
is usually detrimental to tumour-initiating ability149. The drug resistance of carcinoma cells 
also seems to be maximal at an intermediate level of EMT-programme activation, but 
plateaus (rather than declines) with further activation of this programme149,184. MET, 
mesenchymal-to-epithelial transition.
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Figure 2. The patterns of epithelial-to-mesenchymal transition (EMT)-programme activation 
during carcinoma progression
a ∣ In primary tumours, activation of the EMT programme enables particular carcinoma cells 
to invade the surrounding stroma; some of these cells eventually enter the systemic 
circulation. b ∣ Circulating tumour cells can demonstrate epithelial and/or mesenchymal 
traits. Indeed, cancer cells in the circulation, whether solitary or in clusters, frequently 
exhibit signs of at least partial EMT82. c ∣ Reversal of the EMT process — that is, activation 
of the mesenchymal-to-epithelial transition (MET) programme — following dissemination 
of carcinoma cells to distant tissues seems to be critical for the outgrowth of metastases from 
many types of carcinoma88,89.
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Figure 3. The contribution of the tumour microenvironment to the activation of the epithelial-to-
mesenchymal transition (EMT) programme
a ∣ Carcinoma-associated fibroblasts (CAFs) are frequently observed at the invasive front of 
tumours, and probably make an important contribution to the induction of EMT in nearby 
carcinoma cells by secreting various cytokines and enzymes. b ∣ The tumour 
microenvironment is often characterized by chronic inflammation; both soluble and cellular 
mediators of tumour-associated inflammation can contribute to the induction of an EMT 
programme in carcinoma cells. c ∣ Hypoxia is another common characteristic of the tumour 
microenvironment. HIF-1, the central mediator of the responses to tumour-associated 
hypoxia, has been demonstrated to trigger an EMT process, involving the prototypic 
transcription factors ZEB1/2, TCF-3, and TWIST1, in carcinoma cells. CCL18, C–C-motif 
chemokine 18; HGF, hepatocyte growth factor; HIF-1, hypoxia-inducible factor 1; MMP, 
matrix metalloproteinase; TGFβ, transforming growth factor β; TNFα, tumour necrosis 
factor α; uPA, urokinase plasminogen activator.
Shibue and Weinberg Page 34
Nat Rev Clin Oncol. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Figure 4. The mechanistic link between the epithelial-to-mesenchymal transition (EMT) 
programme and cancer stem cell (CSC) status
a ∣ The EMT programme enables carcinoma cells to interact productively with the 
surrounding extracellular matrix (ECM) proteins. Such changes in cell interactions with the 
ECM, in turn, reinforce the tumour-initiating ability of cancer cells with an active EMT 
programme. In particular, EMT enables the efficient development by carcinoma cells of 
integrin-containing mature adhesion plaques, and these plaques, once formed, trigger 
signalling pathways critical to the proliferation of cancer cells, such as those involving focal 
adhesion kinase (FAK) and extracellular signal-related kinase (ERK). b ∣ The activation of 
the EMT programme results in the establishment of several autocrine signalling loops, 
including the transforming growth factor β (TGFβ) and canonical and/or noncanonical Wnt 
pathways. These signalling loops contribute to the CSC properties of cells with an active 
EMT programme. BMPs, bone morphogenetic proteins; DKK1, Dickkopf-related protein 1; 
FLPs, filopodium-like protrusions; SFRP1, secreted Frizzled-related protein 1.
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Figure 5. The mechanism underlying epithelial-to-mesenchymal transition (EMT)-dependent 
acquisition of therapeutic resistance
a ∣ EMT-associated downregulation of multiple apoptotic signalling pathways, enhanced 
drug efflux, and slow cell proliferation all contribute to enhance the general resistance of 
carcinoma cells to anticancer drugs. b ∣ In addition, the EMT-associated transcription factor 
Snail induces the expression of the AXL receptor tyrosine kinase on the surface of 
carcinoma cells. AXL signalling, triggered by the binding of its ligand growth arrest-specific 
protein 6 (GAS6), enables Snail-expressing carcinoma cells to override cytostatic effects of 
EGFR blockade with small-molecule inhibitors (such as erlotinib) or antagonistic 
monoclonal antibodies. c ∣ The EMT programme also activates several processes that enable 
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carcinoma cells to evade the lethal effect of cytotoxic T cells. These changes include 
elevated expression of programmed cell death 1 ligand 1 (PD-L1), which binds to the 
programmed cell death protein 1 (PD-1) inhibitory immune-checkpoint receptor that is 
expressed by cytotoxic T cells and thereby diminishes their function; and increased secretion 
of thrombospondin-1 (TSP-1), which promotes the development of regulatory T cells within 
the tumour microenvironment that ultimately suppress the activity of cytotoxic T cells.
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Table 1
EMT–CSC connections in various carcinoma types
Experimental system Observations Refs
Breast carcinoma
HMLER human mammary 
epithelial cells
• Epithelial-to-mesenchymal transition (EMT)-programme activation in HMLER 
cells, induced either by the ectopic expression of TWIST1 or Snail, or by treatment 
with transforming growth factor β (TGFβ), confers multiple cancer stem cell (CSC) 
properties; these include a CSC-like cell-surface marker expression profile 
(CD44high/CD24low) as well as enhanced in vitro tumour sphere formation and in 
vivo tumour-seeding abilities
• Naturally occurring CD44high/CD24low HMLER-cell subpopulation displays signs of 
EMT-programme activation, including reduced expression of CDH1 (encoding E-
cadherin) and increased expression of the CDH2, VIM, and FN1 mRNAs (encoding 
N-cadherin, vimentin, and fibronectin, respectively).
27,31
Clinical samples (metaplastic or 
claudin-low subtypes)
The clinical samples of metaplastic and claudin-low subtypes of breast cancer simultaneously 
display a CSC-like profile of cell-surface markers (CD44high/CD24low) and signs of EMT-
programme activation, which include reduced expression ofCDH1 mRNA
190
Clinical samples The expression of miR-200c, an antagonist of the EMT programme, is reduced in the CSC fraction 
(CD44high/CD24low) compared with the non-CSC population of clinical breast cancer samples
191
Lung carcinoma
H1299 human non-small-cell 
lung cancer (NSCLC) cell line
The CD44high subpopulation of H1299 cells exhibits signs of EMT-programme activation 
(including increased expression of CDH2 and VIM mRNAs) and enhanced tumour-seeding ability 
in nude mice
192
LC31 human NSCLC cell line TGFβ-induced EMT in LC31 cells confers elevated expression of the OCT4, NANOG, SOX2, 
KIT, and CD133 proteins, an increased potential for tumour sphere formation, and an enhanced 
tumour-seeding ability
193
Prostate carcinoma
PC3 human prostate cancer cell 
line
The induction of EMT by the ectopic expression of platelet-derived growth factor D (PDGF-D) in 
PC3 cells increases their in vitro tumour sphere formation and in vivo tumour-seeding abilities
194
Tumour cells from a Pten-null 
and KrasG12D-driven mouse 
prostate cancer model
Mesenchymal cell subpopulation (epithelial cell adhesion molecule (EpCAM)low/CD24low) of 
these tumour cells exhibits an enhanced ability to form tumour spheres, compared with that of a 
more epithelial cell subpopulation
30
Pancreatic carcinoma
Multiple human pancreatic 
cancer cell lines
The knockdown of zinc finger E-box-binding homeobox (ZEB1) expression in Panc1 and 
MiaPaCa2 human pancreatic cancer cell lines reduces their potentials forin vitro tumour sphere 
formation and in vivo tumour seeding
32
Clinical samples Expression of the ZEB1 transcription factor is associated with tumour recurrence after surgery in 
pancreatic cancer clinical samples
32
Head and neck carcinoma
Clinical samples • The CSC populations (CD44high/CD24low/aldehyde dehydrogenase (ALDH)+) of 
head and neck cancer clinical samples exhibit signs of EMT-programme activation, 
including increased expression of Snail and vimentin, as well as reduced expression 
of E-cadherin
• Knockdown of Snail expression in these CSC subpopulations results in a reduced 
ability for tumour sphere formation
28
Colon carcinoma
Clinical samples The CSC subpopulations (CD133high/CD26high) of colon cancer clinical samples exhibit signs of 
EMT-programme activation, including increased expression of N-cadherin and vimentin, as well as 
reduced expression of E-cadherin
29
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Table 2
Therapy resistance conferred by epithelial-to-mesenchymal transition (EMT)
Therapeutic agent Observations Refs
Inhibition of apoptotic signalling
Cisplatin Slug blocks p53-mediated transcriptional induction of PUMA (also known as BBC3, 
encoding Bcl-2-binding component 3) expression by directly repressing the PUMA 
promoter region; multiple lung adenocarcinoma cell lines acquire cisplatin resistance 
through this mechanism
195,196
Tumour necrosis factor α (TNFα) 
treatment; γ-irradiation
Snail confers resistance against multiple apoptosis-inducing stimuli, in part by 
promoting AKT activation, upregulating the expression of the pro-survival protein Bcl-
XL, and delaying cell-cycle progression
197,198
TNF-related apoptosis-inducing ligand 
(TRAIL)
EMT-programme activation diminishes E-cadherin-mediated clustering of the TRAIL 
receptors DR4 and DR5, thereby making carcinoma cells resistant to TRAIL-induced 
apoptosis
199
Enhancement of drug efflux
Doxorubicin EMT-programme activation induces the expression of multiple members of the ATP-
binding cassette (ABC) transporter family, thereby rendering these cells resistant to 
doxorubicin.
200
Protection against molecular targeted agents
EGFR inhibitors The activation of EMT and subsequent expression of AXL receptor tyrosine kinase 
confer resistance to EGFR inhibitors onEGFR-mutant non-small-cell lung carcinoma 
(NSCLC) cells
201,202
EGFR inhibitors; PI3K inhibitors An EMT-associated gene-expression signature predicts the resistance of NSCLC cells 
to EGFR inhibitors and PI3K inhibitors
163
Desensitization to immunotherapy
Dendritic cell (DC)-mediated 
immunotherapy (intratumoral injection of 
DCs pulsed with a tumour antigen)
Snail expression in melanoma cells contributes to resistance to DC-mediated and CTL-
mediated immunotherapy via enhanced thrombospondin-1 expression and resultant 
induction of immunosuppressive regulatory T cells within the tumour tissue
203
Immune-checkpoint inhibition Zinc finger E-box-binding homeobox (ZEB1)-mediated activation of EMT in NSCLC 
cells relieves miR-200-mediated repression of programmed cell death 1 ligand 1 (PD-
L1) expression, a major inhibitory ligand for the programmed cell death protein 1 
(PD-1) immune-checkpoint protein on CD8+ CTLs. This effect sensitizes these cells to 
immunotherapies targeting the PD-1 PD-L1 axis, while potentially conferring on them 
resistance to other strategies of activating antitumour immunity, such as the functional 
blockade of another immune-checkpoint protein, CTLA-4
204
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